Presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use was written by Amigo, Morgan;Hoffman, Kalyn;Chung, Catherine;Lustberg, Maryam;Wesolowski, Robert;VanDeusen, Jeffrey;Stover, Daniel;Suarez, Gabriel Tinoco;Cherian, Mathew;Kaffenberger, Benjamin;Dulmage, Brittany. And the article was included in Journal of the American Academy of Dermatology in 2022.Synthetic Route of C24H29N7O2 This article mentions the following:
It discusses on presentation and management of diverse cutaneous reactions after cyclin-dependent kinase 4/6 inhibitor use. Inpatient data from 2016-2020 was used to identify 9 patients with hormone receptor breast cancer and patient with liposarcoma who had received treatment with CDK 4/6i and experienced the development of cutaneous reactions. Palbociclib was the initial CDK4/6i used in 9 of the 10 cases and abemaciclib the initial agent in. The average time between drug initiation and the report of a cutaneous reaction was 6.8 mo, with a range of 21 days to 13 mo. The morphol. of the reactions included morbilliform eruptions with mucosal erosions, inflamed actinic keratoses (AKs), psoriasiform dermatitis with or without pustulosis, pustular dermatoses, and palmoplantar dermatitis. The agents used to treat these adverse cutaneous reactions represent commonly prescribed therapeutics in the field of dermatol., except for methylprednisolone, and have low adverse effect profiles. Understanding the potential morphol. and distribution of CDK4/6i-induced cutaneous reactions allows for faster recognition, accurate diagnosis, and appropriate therapeutic management to continue oncol. therapies, leading to more favorable outcomes. In the experiment, the researchers used many compounds, for example, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2Synthetic Route of C24H29N7O2).
6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one (cas: 571190-30-2) belongs to piperazine derivatives. Piperazine causes primary dermal irritation and skin burns at high concentrations. Piperazine also causes eye irritation in humans. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Synthetic Route of C24H29N7O2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics